Diagnosis and treatments relating to her3 inhibitors
AssigneeGenentech, Inc.
InventorsLukas Amler, David Shames
Life of this patent
Estimating the term…
Abstract
The present application describes the use of NRG1 overexpression as a selection criterion for treating cancer patients with a HER3 inhibitor, such as a bispecific HER3/EGFR inhibitor, and methods of treating those patients.
Claims47
A method of treating a type of cancer in a patient comprising administering a therapeutically effective amount of a HER3 inhibitor to the patient, wherein the patient, prior to administration of the HER3 inhibitor, was diagnosed with a cancer which overexpresses NRG1.
A method of treating head and neck squamous cell carcinoma (HNSCC) in a patient comprising administering a therapeutically effective amount of a bispecific HER3/EGFR inhibitor to the patient, wherein the patient, prior to administration of the bispecific HER3/EGFR inhibitor, was diagnosed with a HNSCC which overexpresses NRG1.
A method for selecting a therapy for a patient with a type of cancer which exhibits autocrine neuregulin-induced signaling comprising determining neuregulin 1 (NRG1) expression in a cancer sample from the patient and selecting a HER3 inhibitor for therapy if the cancer sample overexpresses NRG1.
A method of quantifying NRG1 expression level in a cancer sample comprising:
- determining the expression level of NRG1 in the sample, and
- quantifying the expression level of NRG1 in the sample relative to the expression level of one or both of AL-137727 and VPS33B in the sample.
Dependencies are inferred from the claim text.